Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Express Scripts
McKesson
Queensland Health
Argus Health
Citi
McKinsey
AstraZeneca

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,399,485

« Back to Dashboard

Which drugs does patent 7,399,485 protect, and when does it expire?

Patent 7,399,485 protects DEXILANT SOLUTAB and PREVACID and is included in two NDAs.

Protection for DEXILANT SOLUTAB has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-one patent family members in eighteen countries.
Summary for Patent: 7,399,485
Title:Rapidly Disintegrable solid preparation
Abstract:A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Sugaya; Masae (Ikeda, JP), Nakano; Yoshinori (Takarazuka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:09/403,429
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,399,485
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Process; Use;

Drugs Protected by US Patent 7,399,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-002 Aug 30, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,399,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10/213049Jul 28, 1998
PCT Information
PCT FiledJuly 27, 1999PCT Application Number:PCT/JP99/04015
PCT Publication Date:February 10, 2000PCT Publication Number: WO00/06126

Non-Orange Book US Patents Family Members for Patent 7,399,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,070,805 Rapidly disintegrable solid preparation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Accenture
Cipla
Deloitte
Chubb
Citi
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.